Please login to the form below

Not currently logged in
Email:
Password:

Pharmaceutical Market Europe (PME)

PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.

From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.

PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.

From: Research

Novartis forges AI alliance with Oxford University

Novartis Gehry Building, Basel, SwitzerlandPart of Novartis drive to become 'data-driven' pharma company

From: Regulatory

FDA adcomm split on Sanofi’s type 1 diabetes drug

Sanofi receptionConcerns rose after Zynquista-treated patients showed an eight-fold increase in DKA

From: Regulatory

Evenity back on track with FDA panel blessing in osteoporosis

FDA headquarters White OakUS drugs regulator first rejected the drug due to cardiovascular concerns

From: Healthcare

NICE gives Lilly’s Verzenios chance to compete with rivals

NICE (National for Health and Clinical Excellence)Breast cancer drug also being appraised in novel combination

Articles

Pharmaceutical Market Europe - January 2019

Just a few years into the New Year, the $74bn acquisition of Celgene by BMS has woken us all up from our post-festive slump with a bang. The merger is the fourth biggest ever, and could spark more multi-billion dollar M&A deals over the next 12 months.

Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app

Editor - Iona Everson

Have your say...

New faces at Lucid, 90Ten and Page & Page

The latest movers in med comms

'Nothing about us without us'

Why patient engagement is essential throughout the entire product life cycle

Meike Wenzel

Gradually, then suddenly

Company extinction is the result of cognitive shortcomings

darwins medicine

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics